Subtotal
$0.00
Shipping
$0
Taxes
$0
Total
$0.00
LuciTram
.jpg)
LuciTram
$315.00
$325.00
Trametinib Tablets 2mg
Qty
COMPOSITION:
Each Tablet contains: 2.254 mg Trametinib dimethyl sulfoxide equivalent to Trametinib……………… 2mg
INDICATION:
LuciTram is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.
LuciTram is indicated, in combination with dabrafenib, for:
· the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.
· the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations.
· the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation.
· the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.
DOSAGE AND USE:
The recommended dosage of LuciTram is 2 mg orally once daily. Take LuciTram at least 1 hour before or at least 2 hours after a meal.
Tablet should be swallowed whole & not chewed or crushed.
STORAGE:
in a dry place and store at 2°C to 8°C.
MANUFACTURED AND MARKETED BY:
LUCIUS PHARMACEUTICALS(LAO) CO., LTD
No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNING:
Keep medicine out of the reach of Children. Do not administered LuciTram in Pregnancy and Lactation patient treatment.
Customer Reviews
Based on 1 review
Write a review
Write a review
Cobus Bester
Cobus Bester on Mar 03, 2023
Can’t wait to start mixin’ with this one! Irba-irr-Up-up-up-up-date your theme!
Report as InappropriateRelated Products
.jpeg)
